Intracranial activity of tepotinib in patients (pts) with MET exon 14 (METex14) skipping NSCLC enrolled in VISION.

被引：6
|
作者：
Patel, Jyoti D.
Le, Xiuning
Veillon, Remi
Anderson, Ian Churchill
Bestvina, Christine M.
Demedts, Ingel
Garassino, Marina Chiara
Mazieres, Julien
Morise, Masahiro
Smit, Egbert F.
Eggleton, S. Peter
OBrate, Aurora
Otto, Gordon
Bruns, Rolf
Schumacher, Karl-Maria
Paik, Paul K.
机构：
[1] Northwestern Univ, Sch Med, Lurie Canc Ctr, Chicago, IL 60611 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] CHU Bordeaux, Serv Malad Resp, Bordeaux, France
[4] St Joseph Heritage Healthcare, Santa Rosa, CA USA
[5] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[6] AZ Delta, Roeselare, Belgium
[7] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[8] CHU Toulouse, Hop Larrey, Toulouse, France
[9] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi, Japan
[10] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands
[11] Merck KGaA, Global Clin Dev, Darmstadt, Germany
[12] Merck KGaA, Global Med Affairs, Darmstadt, Germany
[13] Merck KGaA, Dept Biostat, Darmstadt, Germany
[14] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9084
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9084
引用
收藏
页数：2
相关论文
共 50 条
  • [41] METex14 ctDNA dynamics & resistance mechanisms detected in liquid biopsy (LBx) from patients (pts) with METex14 skipping NSCLC treated with tepotinib.
    Paik, Paul K.
    Veillon, Remi
    Felip, Enriqueta
    Cortot, Alexis
    Sakai, Hiroshi
    Mazieres, Julien
    Thomas, Michael
    Reinmuth, Niels
    Raskin, Jo
    Conte, Pier Franco
    Garassino, Marina Chiara
    Iams, Wade Thomas
    Griesinger, Frank
    Kowalski, Dariusz M.
    Stroh, Christopher
    Juraeva, Dilafruz
    Scheuenpflug, Juergen
    Johne, Andreas
    Le, Xiuning
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] Liquid biopsy to detect MET exon 14 skipping (METex14) and MET amplification in patients with advanced NSCLC: Biomarker analysis from VISION study
    Le, Xiuning
    Kowalski, Dariusz
    Cho, Byoung Chul
    Conte, Pierfranco
    Felip, Enriqueta
    Garassino, Marina Chiara
    Viteri, Santiago
    Chang, Gee-Chen
    Richart, John
    Paz-Ares, Luiz
    Juraeva, Dilafruz
    Straub, Josef
    Stroh, Christopher
    Paik, Paul
    CANCER RESEARCH, 2020, 80 (16)
  • [43] Liquid biopsies (LBx) and tissue biopsies (TBx) for identifying MET exon 14 (METex14) skipping in advanced NSCLC: Analyses from the phase II VISION study of tepotinib
    Rolfo, C. D.
    Grupp, A. M. OBrate
    Menzel, C.
    Bruns, R.
    Juraeva, D.
    Stroh, C.
    Johne, A.
    Paik, P. K.
    ANNALS OF ONCOLOGY, 2023, 34
  • [44] ABN401 in patients with NSCLC with MET exon 14 (METex14) skipping: Result from the pilot expansion study
    Lee, Dae Ho
    Han, Ji-Youn
    Lemech, Charlotte Rose
    Millward, Michael
    Roohullah, Aflah
    Choi, Jun Young
    Park, Kyung Eui
    Kim, Na Young
    Im, Sunyhe
    Rajasekaran, Nirmal
    Lee, Sangsuk
    Moon, Hanlim
    Hwang, Sunjin
    Shin, Youngkee
    Lee, Se-Hoon
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [45] US health utility in advanced non-small cell lung cancer (NSCLC) patients harboring MET exon 14 (METex14) skipping mutations treated with tepotinib
    Paik, Paul K.
    Yang, Mo
    Knowles, Emma
    Hatswell, Anthony
    Vioix, Helene
    Liu, Frank Xiaoqing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [46] Safety of Tepotinib in Patients With MET Exon 14 Skipping NSCLC and Recommendations for Management
    Veillon, Remi
    Sakai, Hiroshi
    Le, Xiuning
    Felip, Enriqueta
    Cortot, Alexis B.
    Smit, Egbert F.
    Park, Keunchil
    Griesinger, Frank
    Britschgi, Christian
    Wu, Yi-Long
    Melosky, Barbara
    Baijal, Shobhit
    de Castro Jr, Gilberto
    Sedova, Michaela
    Berghoff, Karin
    Otto, Gordon
    Paik, Paul K.
    CLINICAL LUNG CANCER, 2022, 23 (04) : 320 - 332
  • [47] NSCLC with METex14 Skipping Mutation Targeted Therapy with Tepotinib closes therapeutic Gap
    Warpakowski, Andrea
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [48] Tepotinib in patients with MET exon 14 skipping NSCLC: Analysis of all patients from VISION Cohorts A and C
    Itchins, Malinda
    Thomas, Michael
    Garassino, Marina
    Felip, Enriqueta
    Sakai, Hiroshi
    Le, Xiuning
    Veillon, Remi
    Smit, Egbert
    Mazieres, Julien
    Cortot, Alexis
    Raskin, Jo
    Viteri, Santiago
    Yang, James
    Ahn, Myung-Ju
    Wu, Yi-Long
    Ma, Rui
    Zhao, Jun
    O'Brate, Aurora
    Berghoff, Karin
    Bruns, Rolf
    Otto, Gordon
    Paik, Paul
    Young, Louise
    RESPIROLOGY, 2023, 28 : 31 - 32
  • [49] Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
    Tanaka, Hisashi
    Taima, Kageaki
    Makiguchi, Tomonori
    Nakagawa, Junichi
    Niioka, Takenori
    Tasaka, Sadatomo
    CANCER COMMUNICATIONS, 2021, 41 (01) : 83 - 87
  • [50] ctDNA Dynamics, Prognostic Markers and Resistance Mechanisms in Tepotinib-Treated METex14 Skipping NSCLC in the VISION Trial
    Le, X.
    Garassino, M. C.
    Ahn, M. -J.
    Felip, E.
    Cortot, A. B.
    Sakai, H.
    Mazieres, J.
    Thomas, M.
    Viteri, S.
    Conte, P.
    Yang, J. C. -H.
    Iams, W. T.
    Griesinger, F.
    Stroh, C.
    Juraeva, D.
    Wang, D.
    Johne, A.
    Paik, P. K.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S94 - S95
12345